PARAMOUNT: DESCRIPTIVE SUBGROUP ANALYSES OF FINAL OVERALL SURVIVAL (OS) FOR THE PHASE III STUDY OF MAINTENANCE PEMETREXED (PEM) VERSUS PLACEBO (PLB) FOLLOWING INDUCTION TREATMENT WITH PEM PLUS CISPLATIN (CIS) FOR ADVANCED NONSQUAMOUS (NS) NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Reck, M. [1 ]
Paz-Ares, L. [2 ]
De Marinis, F. [3 ]
Molinier, O. [4 ]
Sahoo, T. Prasad [5 ]
Laack, E. [6 ]
John, W. [7 ]
Zimmermann, A. [7 ]
Visseren-Grul, C. M. [8 ]
Gridelli, C. [9 ]
机构：
[1] Hosp Grosshansdorf, Grosshansdorf, Germany
[2] Univ Hosp Virgen del Rocio, Inst Biomed Sevilla 2, Seville, Spain
[3] Azienda Osped S Camillo Forlanini, Pulomonary Oncol Unit 1, Rome, Italy
[4] Le Mans Reg Hosp, Le Mans, France
[5] Jawaharlal Nehru Canc Hosp & Res Ctr, Bhopal, India
[6] Ambulantes Krebszentrum Hamburg, Hamburg, Germany
[7] Eli Lilly & Co, Oncol, Indianapolis, IN 46285 USA
[8] Eli Lilly, Oncol Europe, Ra Houten, Netherlands
[9] UO Oncol Med SG Moscati Hosp, Avellino, Italy
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：404 / 404
页数：1
相关论文
共 50 条
  • [1] PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC).
    Paz-Ares, Luis
    De Marinis, Filippo
    Dediu, Mircea
    Thomas, Michael
    Pujol, Jean-Louis
    Bidoli, Paolo
    Molinier, Oliver
    Sahoo, Tarini Prasad
    Laack, Eckart
    Reck, Martin
    Jaime, Jesus Corral
    Melemed, Symantha
    John, William J.
    Chouaki, Nadia
    Zimmermann, Annamaria
    Visseren-Grul, Carla
    Gridelli, Cesare
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Reck, Martin
    Paz-Ares, Luis G.
    de Marinis, Filippo
    Molinier, Olivier
    Sahoo, Tarini Prasad
    Laack, Eckart
    John, William
    Zimmermann, Annamaria H.
    Visseren-Grul, Carla
    Gridelli, Cesare
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (02) : 205 - 213
  • [3] Overall survival (OS) of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC): final results of a phase Ill study (PARAMOUNT)
    Laack, E.
    Reck, M.
    Schumann, C.
    Eschbach, C.
    Kimmich, M.
    Brandts, C.
    Paz-Ares, L. G.
    De Marinis, F.
    Dediu, M.
    Pujol, J.-L.
    Bidoli, P.
    Molinier, O.
    Sahoo, T. P.
    Corral, J.
    Melemed, S. A.
    John, W. J.
    Chouaki, N.
    Zimmermann, A. H.
    Visseren-Grul, C. M.
    Leschinger, M., I
    Thomas, M.
    ONKOLOGIE, 2012, 35 : 36 - 37
  • [4] PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)
    Paz-Ares, L. G.
    De Marinis, F.
    Dediu, M.
    Thomas, M.
    Pujol, J.
    Bidoli, P.
    Molinier, O.
    Sahoo, T. P.
    Laack, E.
    Reck, M.
    Corral, J.
    Melemed, S. A.
    John, W. J.
    Chouaki, N.
    Zimmerman, A.
    Grul, C. M. Visseren
    Gridelli, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)
    Paz-Ares, L. G.
    De Marinis, F.
    Dediu, M.
    Thomas, M.
    Pujol, J.
    Bidoli, P.
    Molinier, O.
    Sahoo, T. P.
    Laack, E.
    Reck, M.
    Corral, J.
    Melem, S. A.
    Grul, C. M. Visseren
    Gridelli, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
  • [6] PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Paz-Ares, Luis G.
    de Marinis, Filippo
    Dediu, Mircea
    Thomas, Michael
    Pujol, Jean-Louis
    Bidoli, Paolo
    Molinier, Olivier
    Sahoo, Tarini Prasad
    Laack, Eckart
    Reck, Martin
    Corral, Jesus
    Melemed, Symantha
    John, William
    Chouaki, Nadia
    Zimmermann, Annamaria H.
    Visseren-Grul, Carla
    Gridelli, Cesare
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) : 2895 - +
  • [7] Pemetrexed (Pem) Maintenance Therapy in Elderly Patients (Pts) With Good Performance Status (PS) - Analysis of PARAMOUNT Phase III Study of Pem Versus Placebo in Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC)
    Gridelli, C.
    Thomas, M.
    Prabhash, K.
    El Kouri, C.
    Blackhall, F.
    Melemed, S.
    Zimmermann, A.
    Chouaki, N.
    Visseren-Grul, C.
    Paz-Ares, L. G.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S613 - S613
  • [8] Final overall survival (OS) results from a phase II study of pemetrexed (Pem) and cisplatin (Cis) with concurrent thoracic radiation (RT) after Pem-Cis induction in patients with unresectable locally advanced (LA) nonsquamous non-small cell lung cancer (NS-NSCLC).
    Novello, Silvia
    Engel-Riedel, Walburga
    Serke, Monika
    Giraud, Philippe
    Visseren-Grul, Carla
    Ameryckx, Sophie
    Soldatenkova, Victoria
    Chouaki, Nadia
    Garrido, Pilar
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer
    Gridelli, Cesare
    Maione, Paolo
    Rossi, Antonio
    REVIEWS ON RECENT CLINICAL TRIALS, 2013, 8 (01) : 23 - 28
  • [10] A RANDOMIZED PHASE 2 STUDY COMPARING MAINTENANCE PEMETREXED (PEM) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS BSC ALONE FOLLOWING INDUCTION TREATMENT WITH PEM-CISPLATIN (CIS) IN ADVANCED NONSQUAMOUS (NONSQ) NON-SMALL CELL LUNG CANCER (NSCLC)
    Meshref, Mohamed
    Gaafar, Rabab M.
    Shehata, Samir
    Hashem, Tarek
    Gerges, Dani Abi
    Azim, Hamdy Abdel
    El-Husseiny, Gamal
    Al-Hussein, Hamed
    Liu, Zhixin
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1263 - S1263
12345